Neurocrine Biosciences NBIX
$150.57 −$6.02 (-3.84%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $150.57 0.00%
Open$156.27
Prev close$156.59
Day range$150.24 – $158.26
Volume1.59M
Market cap$15.24B
P/E (TTM)22.3
Dividend yield–
NBIX Stock News
Headlines matching Neurocrine Biosciences or the NBIX ticker, most recent first.
- Citi Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $253
- Citi Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $253 Positive
- UBS Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $214 Negative
- Bernstein Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $218
- Neurocrine (NBIX) Receives a Buy From CCB Intl.
- RBC Capital Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $198
- Morgan Stanley Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Raises Target Price to $183 Positive
- J.P. Morgan Reaffirms Their Buy Rating on Neurocrine (NBIX)
- J.P. Morgan Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $217
- A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $194 to $249
- CCORF Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $210 Positive
- Citi Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $249
- Morgan Stanley Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Maintains Target Price $182
- BMO Capital Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Maintains Target Price $190
- Evercore Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $215 Positive
No comments yet — be the first to weigh in on NBIX.
Sign in to join the discussion.